|
시장보고서
상품코드
2087808
국소 지혈제 시장 : 제품 유형, 제제, 재료 유래, 흡수성, 용도, 최종사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)Topical Hemostat Market by Product Type, Formulation, Material Source, Absorbability, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
360iResearch
국소 지혈제 시장은 2032년까지 연평균 복합 성장률(CAGR) 8.06%로 115억 1,000만 달러에 달할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 66억 9,000만 달러 |
| 추정 연도 : 2026년 | 72억 달러 |
| 예측 연도 : 2032년 | 115억 1,000만 달러 |
| CAGR(%) | 8.06% |
국소 지혈제 시장에 대한 개요
국소 지혈제는 압박, 봉합, 클립, 소작, 결찰 등 기존의 기술로는 충분하지 않거나 실용적이지 않은 경우에 사용되는 외과적 출혈 제어 제품에서 필수적인 범주입니다. 이 시장에는 흡수성 기계적 지혈제, 활성 트롬빈 계열 제품, 유동성 지혈 매트릭스, 피브린 실란트, 합성 실란트, 심혈관, 정형외과, 뇌신경외과, 일반외과, 외상, 산부인과, 최소 침습 수술 등에서 사용되는 복합 제품이 포함됩니다.
국소 지혈 요법을 재구축하는 혁신적인 변화
국소 지혈제 시장은 범용 외과 보조재에서 시술에 특화된 근거 기반 지혈 솔루션으로 전환되고 있습니다. 외과 의사들은 출혈의 정도, 해부학적 제약, 흡수성, 팽윤 특성, 투여 형태, 최소 침습 로봇 수술의 워크플로우와의 적합성을 바탕으로 제품을 선택하는 경향이 점점 더 강해지고 있습니다. 이러한 변화로 인해, 즉시 사용할 수 있는 유동성 지혈제, 스프레이형 실란트, 접근이 어려운 좁은 수술 부위를 위해 설계된 어플리케이터가 주목받고 있습니다.
국소 지혈제에 대한 인공지능의 누적 영향
인공지능(AI)은 수요 계획, 증거 통합, 제조 최적화, 품질 모니터링, 임상 의사결정 지원을 통해 국소 지혈제의 밸류체인에 영향을 미치기 시작하고 있습니다. 병원에서는 AI를 활용한 분석을 통해 수술 유형, 외과의사의 선호 패턴, 수혈 위험, 제품 사용 현황의 편차를 파악할 수 있으며, 이는 공급망 담당 팀이 임상적 선택의 폭을 좁히지 않으면서도 혼합 세트의 표준화를 추진하는 데 도움이 되고 있습니다.
국소 지혈제 수요에 관한 주요 지역별 분석
북미는 첨단 외과 인프라, 생물 유래 및 복합 지혈제의 높은 보급률, 확립된 혈액 관리 관행, 그리고 병원들이 FDA 승인 또는 허가 제품을 중시하고 있다는 점 등으로 인해, 국소용 지혈제 시장에 있어 여전히 가치가 높은 지역입니다. 유럽은 성숙한 수술 수요, 다수 국가에서의 중앙 집중식 조달, 임상 문서화, 시판 후 조사, 추적성, 실세계 데이터(RWE)의 중요성을 강조한 EU MDR(의료기기 규정)이 특징입니다.
전략적 시장 포지셔닝에 활용된 주요 그룹 분석
지역별 블록 중에서는 G7 국가들이 높은 수술 시행 빈도, 확립된 보험 급여 제도, 첨단 수술실 인프라, 엄격한 제품 평가를 통해 프리미엄 국소 지혈제의 도입을 주도하고 있습니다. 유럽연합(EU)이 영향력을 행사하는 이유는 EU MDR 준수가 회원국뿐만 아니라, CE 마크가 부착된 제품 포트폴리오를 활용해 국제적인 등록 및 조달 시장에 접근하는 전 세계 제조업체들에게도 영향을 미치기 때문입니다. NATO 시장은 외과 수술 대응 능력, 외상 관리, 비상사태 대비, 공급 탄력성이 전략적 우선순위로 자리 잡고 있는 고소득국의 의료 시스템과 크게 겹칩니다.
우선적인 국소 지혈제 시장의 주요 국가에 대한 분석
미국은 수술 건수가 많고, 전문 의료 서비스가 잘 갖춰져 있으며, 병원의 혈액 관리 체계가 잘 정립되어 있고, FDA 규제 하에 있는 지혈제에 대한 확립된 승인 절차가 마련되어 있어, 첨단 국소 지혈제 시장에 있어 가장 큰 상업적 기회를 제공합니다. 캐나다에서는 근거, 안전성, 의료 기술 평가, 주별 조달 규정이 중시되고 있습니다. 한편, 멕시코에서는 민간 병원의 성장과 공공 부문의 비용 절감 노력이 맞물려 있습니다. 브라질은 3차 의료 체계와 복잡한 수술을 바탕으로 라틴아메리카 국소 지혈제 시장의 선도적 위치를 차지하고 있으나, 보험 급여 제도의 불균일성과 입찰 동향이 시장 보급에 영향을 미치고 있습니다.
국소 지혈제 산업의 선두주자가 되기 위한 실천적 제안
산업을 선도하는 기업들은 국소 지혈제의 성능과 출혈 관련 합병증 감소, 수혈 회피, 수술 시간 단축, 업무 흐름 효율화, 총 의료비 절감을 연결 짓는 차별화된 임상적 근거를 우선시해야 합니다. 제품 포트폴리오는 출혈의 중증도, 수술 유형, 투여 경로, 흡수성, 부종 위험, 준비 시간에 따라 세분화되어야 하며, 이를 통해 병원은 복잡한 출혈에 대해 부적절한 처치를 하지 않으면서도 제품 선정 과정을 표준화할 수 있게 됩니다.
조사 방법론과 증거 체계
본 요약본은 규제 데이터베이스, 제품 라벨, 임상 문헌, 병원 혈액 관리 지침, 공중보건 통계, 보험 급여 기준, 조달 동향, 공인 기관의 거시경제 지표 등 공개되고 검증 가능한 정보원을 활용한 체계적인 2차 조사 접근법에 기반을 두고 있습니다. 시장 분석에서는 제품 분류, 외과적 용도, 규제 현황, 지역별 가용성, 조달 동향, 경쟁 구도 등이 고려됩니다.
결론: 국소 지혈제의 전략적 전망
외과 팀이 보다 신속하고 안전하며, 각 수술에 최적화된 출혈 제어 방안을 모색함에 따라, 국소 지혈제 시장은 앞으로도 지속적인 전략적 중요성을 유지할 것으로 전망됩니다. 경쟁에서 성공하기 위해서는 제품의 가용성뿐만 아니라, 명확한 임상적 차별화, 신뢰할 수 있는 공급, 외과의사가 사용하기 편리한 투여 방법, 규제 대응 준비, 총비용 측면에서의 가치를 입증하는 근거가 필요합니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향, 2026년
제7장 국소 지혈제 시장 : 제품 유형별
제8장 국소 지혈제 시장 : 제제별
제9장 국소 지혈제 시장 : 재료 유래별
제10장 국소 지혈제 시장 : 흡수성별
제11장 국소 지혈제 시장 : 용도별
제12장 국소 지혈제 시장 : 최종사용자별
제13장 국소 지혈제 시장 : 유통 채널별
제14장 국소 지혈제 시장 : 지역별
제15장 국소 지혈제 시장 : 그룹별
제16장 국소 지혈제 시장 : 국가별
제17장 경쟁 구도
제18장 기업 개요
LSH 26.07.23The Topical Hemostat Market is projected to grow by USD 11.51 billion at a CAGR of 8.06% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 6.69 billion |
| Estimated Year [2026] | USD 7.20 billion |
| Forecast Year [2032] | USD 11.51 billion |
| CAGR (%) | 8.06% |
Executive Introduction to the Topical Hemostat Market
Topical hemostats are an essential category of surgical bleeding control products used when conventional techniques such as pressure, sutures, clips, cautery, or ligation are insufficient or impractical. The market spans absorbable mechanical agents, active thrombin-based products, flowable hemostatic matrices, fibrin sealants, synthetic sealants, and combination products used across cardiovascular, orthopedic, neurosurgical, general, trauma, obstetric, and minimally invasive procedures.
Demand is supported by persistent surgical volume, population aging, rising comorbidity burden, wider use of anticoagulant and antiplatelet therapies, and the clinical priority of reducing blood loss, transfusion exposure, operating-room time, and postoperative complications. For manufacturers, hospitals, and investors, competitive advantage is increasingly tied to proven hemostatic performance, fast preparation, biocompatibility, transparent total-cost evidence, and regulatory compliance across major markets.
Transformative Shifts Reshaping Topical Hemostasis
The topical hemostat landscape is moving from commodity surgical adjuncts toward procedure-specific, evidence-led bleeding control solutions. Surgeons increasingly select products based on bleeding intensity, anatomical constraints, absorbability, swelling profile, delivery format, and compatibility with minimally invasive and robotic workflows. This shift favors ready-to-use flowables, sprayable sealants, and applicators designed for narrow or difficult-to-access surgical fields.
Regulatory expectations are also transforming the market. The U.S. FDA treats many thrombin, fibrin, and combination hemostats as biologics, devices, or combination products depending on composition and claims, while the European Union Medical Device Regulation has increased clinical evidence, post-market surveillance, and documentation requirements. As a result, suppliers with robust clinical data, validated quality systems, and reliable plasma, collagen, gelatin, cellulose, or synthetic polymer sourcing are better positioned than firms competing primarily on price.
Cumulative Impact of Artificial Intelligence on Topical Hemostats
Artificial intelligence is beginning to influence the topical hemostat value chain through demand planning, evidence synthesis, manufacturing optimization, quality monitoring, and clinical decision support. In hospitals, AI-enabled analytics can identify procedure types, surgeon preference patterns, transfusion risk, and product utilization variance, helping supply-chain teams standardize formularies without compromising clinical choice.
For manufacturers, machine learning can improve batch consistency, predict raw-material deviations, monitor sterilization and packaging quality, and accelerate post-market surveillance by analyzing complaint trends, adverse-event narratives, and real-world safety signals. AI does not replace surgeon judgment at the point of bleeding control, but it can make product selection, inventory planning, clinical education, and health-economic evidence more precise, especially where hospitals are under pressure to reduce waste and prove value.
Key Regional Insights Across Topical Hemostat Demand
North America remains a high-value region for topical hemostats because of advanced surgical infrastructure, strong adoption of biologic and combination hemostats, established blood-management practices, and hospital focus on FDA-cleared or FDA-approved products. Europe is shaped by mature surgical demand, centralized procurement in many countries, and the EU MDR, which has raised the importance of clinical documentation, post-market surveillance, traceability, and real-world evidence.
Asia-Pacific is an expanding opportunity base, driven by rising surgical access, private hospital investment, medical tourism, and growing domestic medtech capacity across China, India, Japan, South Korea, Australia, and ASEAN economies. Latin America, led by Brazil and Mexico, shows increasing demand in tertiary hospitals and private networks but remains sensitive to reimbursement, tender pricing, and currency volatility. The Middle East is supported by specialty hospital investment, trauma and complex-care capabilities, and GCC healthcare modernization, while Africa offers long-term potential through trauma care, maternal health, and surgical-capacity expansion, although affordability, training, cold-chain needs for some biologic products, and distribution reliability remain key constraints.
Key Group Insights for Strategic Market Positioning
Among regional blocs, the G7 anchors premium topical hemostat adoption through high procedure intensity, established reimbursement pathways, advanced operating-room infrastructure, and stringent product evaluation. The European Union is influential because EU MDR compliance affects not only member states but also global manufacturers that use CE-marked portfolios for international registration and procurement access. NATO markets overlap significantly with high-income healthcare systems where surgical readiness, trauma management, emergency preparedness, and supply resilience are strategic priorities.
BRICS economies represent a dual opportunity: China, India, and Brazil are expanding access to advanced surgery, while domestic production, tender discipline, and cost containment increasingly shape procurement. ASEAN is important for medical tourism, private hospital chains, and improving surgical infrastructure in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is a premium regional cluster where hospital modernization, specialist centers, government-funded healthcare investment, and international accreditation support adoption of advanced hemostatic products when supported by clinical and economic evidence.
Key Country Insights in Priority Topical Hemostat Markets
The United States is the largest commercial opportunity for advanced topical hemostats because of high surgical intensity, strong specialty care, hospital blood-management initiatives, and established pathways for FDA-regulated hemostatic agents. Canada emphasizes evidence, safety, health technology assessment, and provincial procurement discipline, while Mexico combines private hospital growth with public-sector cost sensitivity. Brazil is Latin America's leading topical hemostat market, supported by tertiary care capacity and complex surgery, although reimbursement variability and tender dynamics affect uptake.
In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature demand shaped by hospital value committees, clinical guidelines, national reimbursement structures, and EU MDR-related evidence requirements, while Russia remains affected by localization, procurement, and geopolitical supply considerations. China and India offer substantial growth as surgical access expands, but pricing, volume-based purchasing, tenders, and local competition are decisive. Japan and South Korea are quality-focused markets with advanced surgical adoption and strict regulatory expectations, while Australia rewards products that demonstrate safety, usability, supply reliability, and measurable value within a well-regulated healthcare system.
Actionable Recommendations for Topical Hemostat Leaders
Industry leaders should prioritize differentiated clinical evidence that links topical hemostat performance to reduced bleeding-related complications, transfusion avoidance, shorter procedure time, improved workflow efficiency, and lower total cost of care. Product portfolios should be segmented by bleeding severity, procedure type, access route, absorbability, swelling risk, and preparation time so hospitals can standardize selection without under-treating complex bleeding.
Manufacturers should strengthen supply-chain resilience for human plasma, bovine, porcine, cellulose, gelatin, collagen, and synthetic inputs while investing in applicator innovation for minimally invasive and robotic surgery. Commercial teams should equip value-analysis committees with real-world evidence, budget-impact models, comparative usability data, and surgeon education. Regulatory teams should align early with FDA, EU MDR, and local requirements to avoid launch delays, documentation gaps, and post-market surveillance deficiencies.
Research Methodology and Evidence Framework
This executive summary is based on a structured secondary-research approach using publicly available and verifiable sources, including regulatory databases, product labeling, clinical literature, hospital blood-management guidance, public health statistics, reimbursement references, procurement signals, and macroeconomic indicators from recognized institutions. Market interpretation considers product class, surgical application, regulatory status, regional access, procurement behavior, and competitive positioning.
Insights are triangulated across clinical evidence, regulatory context, healthcare infrastructure, and commercial adoption signals. The methodology excludes unsupported claims, market sizing, market share, and forecasting, and emphasizes data-backed patterns such as surgical access expansion, aging demographics, increased anticoagulant use, regulatory scrutiny, hospital demand for value-based procurement, and the growing role of real-world evidence in medical product evaluation.
Conclusion: Strategic Outlook for Topical Hemostats
The topical hemostat market is positioned for sustained strategic relevance as surgical teams seek faster, safer, and more procedure-specific bleeding control. Competitive success will depend on more than product availability; it will require clear clinical differentiation, reliable supply, surgeon-friendly delivery, regulatory readiness, and evidence that supports total-cost value.
As AI, advanced biomaterials, minimally invasive surgery, and stricter regulatory expectations reshape the category, manufacturers that combine innovation with real-world outcomes data will be best placed to earn hospital trust. Regional expansion remains attractive, but durable growth will come from aligning premium performance with local reimbursement, procurement expectations, surgical workflow realities, and patient-safety priorities.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Topical Hemostat Market, by Product Type
- 7.1. Mechanical Hemostats
- 7.1.1. Gelatin-based
- 7.1.2. Collagen-based
- 7.1.3. Oxidized Regenerated Cellulose
- 7.1.4. Polysaccharide-based
- 7.2. Active Hemostats
- 7.3. Flowable Hemostats
- 7.4. Caustic Hemostats
- 7.4.1. Silver Nitrate
- 7.4.2. Ferric Subsulfate
- 7.4.3. Aluminum Chloride
8. Topical Hemostat Market, by Formulation
- 8.1. Sponges
- 8.2. Powders
- 8.3. Sheets
- 8.4. Pads
- 8.5. Foams
- 8.6. Gels
9. Topical Hemostat Market, by Material Source
- 9.1. Biological Materials
- 9.2. Plant-derived Materials
- 9.3. Synthetic Materials
10. Topical Hemostat Market, by Absorbability
- 10.1. Absorbable Hemostats
- 10.2. Non-Absorbable Hemostats
11. Topical Hemostat Market, by Application
- 11.1. Cardiovascular Surgery
- 11.1.1. Coronary Artery Bypass Grafting
- 11.1.2. Valve Repair & Replacement
- 11.1.3. Vascular Grafting
- 11.2. Dental & Oral Surgery
- 11.2.1. Tooth Extraction
- 11.2.2. Periodontal Surgery
- 11.2.3. Implant Placement
- 11.3. General Surgery
- 11.3.1. Abdominal
- 11.3.2. Gastrointestinal
- 11.3.3. Hepatobiliary
- 11.3.4. Colorectal
- 11.4. Neurosurgery
- 11.4.1. Cranial
- 11.4.2. Spinal Neurosurgery
- 11.4.3. Tumor Resection Procedures
- 11.5. Orthopedic Surgery
- 11.5.1. Joint Replacement
- 11.5.2. Spine
- 11.6. Gynecological Surgery
- 11.6.1. Hysterectomy
- 11.6.2. Myomectomy
- 11.6.3. Endometriosis
12. Topical Hemostat Market, by End User
- 12.1. Ambulatory Surgery Centers
- 12.2. Specialty Clinics
- 12.3. Hospitals
- 12.3.1. Private Hospitals
- 12.3.2. Public Hospitals
- 12.4. Military & Defense Settings
- 12.5. Homecare Settings
13. Topical Hemostat Market, by Distribution Channel
- 13.1. Online
- 13.2. Offline
14. Topical Hemostat Market, by Region
- 14.1. Asia-Pacific
- 14.2. North America
- 14.3. Latin America
- 14.4. Europe
- 14.5. Middle East
- 14.6. Africa
15. Topical Hemostat Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
16. Topical Hemostat Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
17. Competitive Landscape
- 17.1. Market Concentration Analysis, 2025
- 17.1.1. Concentration Ratio (CR)
- 17.1.2. Herfindahl Hirschman Index (HHI)
- 17.2. Recent Developments & Impact Analysis, 2025
- 17.3. Product Portfolio Analysis, 2025
- 17.4. Benchmarking Analysis, 2025
18. Company Profiles
- 18.1. Aegis Lifesciences Private Limited
- 18.2. Axio Biosolutions Pvt Ltd
- 18.3. B.Braun Melsungen AG
- 18.4. Baxter International, Inc.
- 18.5. Becton, Dickinson and Company
- 18.6. Betatech Medical
- 18.7. BioCer Entwicklungs-GmbH
- 18.8. Bristol-Myers Squibb Company
- 18.9. Dilon Technologies Inc
- 18.10. GELITA MEDICAL GmbH
- 18.11. Hemostasis, LLC
- 18.12. Integra LifeSciences Corporation
- 18.13. Johnson & Johnson Services, Inc.
- 18.14. Marine Polymer Technologies, Inc.
- 18.15. Medline Industries, LP
- 18.16. Medtrade Products Ltd
- 18.17. Medtronic PLC
- 18.18. Meril Life Sciences Pvt. Ltd
- 18.19. Pfizer Inc.
- 18.20. Southmedic Inc.
- 18.21. Stryker Corporation
- 18.22. SYMATESE SAS
- 18.23. Takeda Pharmaceutical Company Limited
- 18.24. Teleflex Incorporated
- 18.25. Zeria Pharmaceutical Co., Ltd.
